385 related articles for article (PubMed ID: 3342397)
1. Antitumor activity and hematotoxicity of a new, substituted dihydrobenzoxazine, FK973, in mice.
Shimomura K; Manda T; Mukumoto S; Masuda K; Nakamura T; Mizota T; Matsumoto S; Nishigaki F; Oku T; Mori J
Cancer Res; 1988 Mar; 48(5):1166-72. PubMed ID: 3342397
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of a novel antitumor antibiotic, quinocarmycin citrate (KW2152).
Fujimoto K; Oka T; Morimoto M
Cancer Res; 1987 Mar; 47(6):1516-22. PubMed ID: 2434218
[TBL] [Abstract][Full Text] [Related]
3. FK317: a novel substituted dihydrobenzoxazine with potent antitumor activity which does not induce vascular leak syndrome.
Naoe Y; Inami M; Matsumoto S; Nishigaki F; Tsujimoto S; Kawamura I; Miyayasu K; Manda T; Shimomura K
Cancer Chemother Pharmacol; 1998; 42(1):31-6. PubMed ID: 9619755
[TBL] [Abstract][Full Text] [Related]
4. A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines.
Tsuruo T; Yusa K; Sudo Y; Takamori R; Sugimoto Y
Cancer Res; 1989 Oct; 49(20):5537-42. PubMed ID: 2790778
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of 7-N-[[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]]-mitomycin C.
Morimoto M; Ashizawa T; Ohno H; Azuma M; Kobayashi E; Okabe M; Gomi K; Kono M; Saitoh Y; Kanda Y
Cancer Res; 1991 Jan; 51(1):110-5. PubMed ID: 1988076
[TBL] [Abstract][Full Text] [Related]
6. A new antitumor antibiotic, FK973: its metabolism in the blood and the antitumor effects of its metabolites on experimental models.
Masuda K; Suzuki A; Nakamura T; Takagaki S; Noda K; Shimomura K; Noguchi H; Shibayama F
Jpn J Pharmacol; 1989 Oct; 51(2):219-26. PubMed ID: 2593379
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic effects of a new antitumor antibiotic, FK973, in malignant glioma.
Moriuchi S; Shimizu K; Yamada M; Mabuchi E; Tamura K; Park KC; Hayakawa T
Anticancer Res; 1991; 11(6):2079-84. PubMed ID: 1776843
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic activity of FK973 against human oral and breast cancer cells.
Wu JZ; Adachi I; Watanabe T
Chin Med J (Engl); 1991 Oct; 104(10):834-7. PubMed ID: 1661225
[TBL] [Abstract][Full Text] [Related]
9. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors.
Koyanagi N; Nagasu T; Fujita F; Watanabe T; Tsukahara K; Funahashi Y; Fujita M; Taguchi T; Yoshino H; Kitoh K
Cancer Res; 1994 Apr; 54(7):1702-6. PubMed ID: 8137285
[TBL] [Abstract][Full Text] [Related]
10. Interstrand DNA-DNA and DNA-protein cross-links by a new antitumor antibiotic, FK973, in L1210 cells.
Masuda K; Nakamura T; Mizota T; Mori J; Shimomura K
Cancer Res; 1988 Sep; 48(18):5172-7. PubMed ID: 3409243
[TBL] [Abstract][Full Text] [Related]
11. In vivo antitumor activity of S 16020-2, a new olivacine derivative.
Guilbaud N; Kraus-Berthier L; Saint-Dizier D; Rouillon MH; Jan M; Burbridge M; Visalli M; Bisagni E; Pierré A; Atassi G
Cancer Chemother Pharmacol; 1996; 38(6):513-21. PubMed ID: 8823492
[TBL] [Abstract][Full Text] [Related]
12. Effect of FK973, a new antitumor antibiotic, on the cell cycle of L1210 cells in vitro.
Nakamura T; Masuda K; Matsumoto S; Oku T; Manda T; Mori J; Shimomura K
Jpn J Pharmacol; 1989 Mar; 49(3):317-24. PubMed ID: 2501546
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of DMP 840: a novel bis-naphthalimide cytotoxic agent with human solid tumor xenograft selectivity.
McRipley RJ; Burns-Horwitz PE; Czerniak PM; Diamond RJ; Diamond MA; Miller JL; Page RJ; Dexter DL; Chen SF; Sun JH
Cancer Res; 1994 Jan; 54(1):159-64. PubMed ID: 8261436
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity and toxicity in animals of BMY-25282, a new mitomycin derivative.
Bradner WT; Rose WC; Schurig JE; Florczyk AP; Huftalen JB; Catino JJ
Cancer Res; 1985 Dec; 45(12 Pt 1):6475-81. PubMed ID: 3933826
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity and mechanism of action of the novel marine natural products mycalamide-A and -B and onnamide.
Burres NS; Clement JJ
Cancer Res; 1989 Jun; 49(11):2935-40. PubMed ID: 2720652
[TBL] [Abstract][Full Text] [Related]
16. MX2, a morpholino anthracycline, as a new antitumor agent against drug-sensitive and multidrug-resistant human and murine tumor cells.
Watanabe M; Komeshima N; Nakajima S; Tsuruo T
Cancer Res; 1988 Dec; 48(23):6653-7. PubMed ID: 3180075
[TBL] [Abstract][Full Text] [Related]
17. Preclinical antitumor activity of an alpha-picoline derivative, penclomedine (NSC 338720), on human and murine tumors.
Plowman J; Harrison SD; Dykes DJ; Paull KD; Narayanan VL; Tobol HK; Martin J; Griswold DP
Cancer Res; 1989 Apr; 49(8):1909-15. PubMed ID: 2702634
[TBL] [Abstract][Full Text] [Related]
18. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M
Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
[TBL] [Abstract][Full Text] [Related]
19. A new antitumor antibiotic, FR-900482. III. Antitumor activity in transplantable experimental tumors.
Shimomura K; Hirai O; Mizota T; Matsumoto S; Mori J; Shibayama F; Kikuchi H
J Antibiot (Tokyo); 1987 May; 40(5):600-6. PubMed ID: 3610819
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human tumor necrosis factor-alpha: evidence of an indirect mode of antitumor activity.
Manda T; Shimomura K; Mukumoto S; Kobayashi K; Mizota T; Hirai O; Matsumoto S; Oku T; Nishigaki F; Mori J
Cancer Res; 1987 Jul; 47(14):3707-11. PubMed ID: 3594435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
